Perelman School of Medicine at the University of Pennsylvania

Penn Institute for Immunology

Jan Joseph Melenhorst

faculty photo
Adjunct Associate Professor of Pathology and Laboratory Medicine
Department: Pathology and Laboratory Medicine
Graduate Group Affiliations

Contact information
SPE South Tower, Rm. 9-105,
3400 Civic Center Boulevard, Blg. 421
Philadelphia, PA 19104-5156
Office: 215.573.6852
Lab: N/A
Education:
BSc (Biology, Geography, Associate Professor in Continuing Education)
Moller Institute, Netherlands, 1988.
MS (Medical Biology)
Nijmegen Katholic University, Netherlands, 1991.
PhD (Immunology)
Leiden University, Netherlands, 1998.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

As a translational immunologist my interest is in improving the potency and safety of adoptive immunogene therapy via correlative studies and product/process development. My translational interest also lies in streamlining the immunogene manufacturing process while maintaining or improving product potency.

Description of Other Expertise

Immunology of human allogeneic hematopoietic stem cell transplantation.

Description of Research Expertise

My expertise is in human T cell immunology and immunogene therapy, understanding and improving the anti-tumor efficacy of gene-engineered T cells for the treatment of cancers.

Selected Publications

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL: Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Mol Ther. pii: S1525-0016(19)30328-4. doi: 10.1016/j.ymthe.2019.07.015. [Epub ahead of print] July 2019.

van Bruggen JAC, Martens AWJ, Fraietta JA, Hofland T, Tonino SH, Eldering E, Levin MD, Siska PJ, Endstra S, Rathmell JC, June CH, Porter DL, Melenhorst JJ, Kater AP, van der Windt GJW: Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T cell efficacy. Blood Page: pii: blood.2018885863, May 2019 Notes: doi: 10.1182/blood.2018885863. Epub ahead of print. No volume or issue at this time.

Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. The Journal of Clinical Investigation 130(6): 2210-2221, Mar 2019 Notes: doi: 10.1172/JCI126397.

Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH.: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 4(4): pii: 127684, Feb 2019.

Chen F, Fraietta JA, June CH, Xu Z, Melenhorst JJ, Lacey SF: Engineered T Cell Therapies from a Drug Development Viewpoint. Engineering 5(1): 140-149, Feb 2019.

Nobles CL, Reddy S, Salas-McKee J, Liu X, June CH, Melenhorst JJ, Davis MM, Zhao Y, Bushman FD. : iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity. Genome Biol. 20(1): 14, Jan 2019.

Alfred L. Garfall, Ehren Dancy, Adam D. Cohen, Wei-Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, and J. Joseph Melenhorst: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma. Blood Advances epub ahead of print, 2019.

Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ*, Beatty GL*. * co-senior authors: Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Cell Mol Gastroenterol Hepatol. 2019 Aug 6. pii: S2352-345X(19)30096-7. doi: 10.1016/j.jcmgh.2019.07.008. [Epub ahead of print] 2019.

Kristen B Long, Regina M Young, Alina C Boesteanu, Megan M Davis, J Joseph Melenhorst, Simon F Lacey, David A Degaramoda, Bruce L Levine, Joseph A Fraietta: CAR T cell therapy of non-hematopoietic malignancies - detours on the road to clinical success. Frontiers in Immunology 9: 2740, Dec 2018 Notes: No issue. Published online 2018 Dec 3. doi: 10.3389/fimmu.2018.02740.

Elise A. Chong, Jakub Svoboda, Sunita Dwivedy Nasta, Daniel J. Landsburg, Nicole Winchell, Ellen Napier, Anthony R. Mato, J. Joseph Melenhorst, Marco Ruella, Simon F Lacey, Carl H June and Stephen J. Schuster: Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas. Blood, American Society of Hematology Annual Meeting, San Diego, CA 132(Suppl 1), Nov 2018 Notes: Poster presentation.

back to top
Last updated: 08/21/2019
The Trustees of the University of Pennsylvania